netFormulary Central Lancashire Formulary NHS
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley and South Ribble CCG
Greater Preston CCG
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.12  Expand sub section  Lipid-regulating drugs
Alirocumab (Praluent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq
 
Link  NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
Evolocumab (Repatha® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq
 
Link  NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
02.12  Expand sub section  Bile acid sequestrants
Colestyramine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
02.12  Expand sub section  Ezetimibe
Ezetimibe (Ezetrol®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
   
02.12  Expand sub section  Fibrates
Bezafibrate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Fenofibrate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
02.12  Expand sub section  Statins to top
Atorvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug Safety Update December 2014: Statins: interactions, and updated advice for atorvastatin
   
Rosuvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Simvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug Safety Update December 2014: Simvastatin: dose limitations with concomitant amlodipine or diltiazem
Link  Drug Safety Update December 2014: Simvastatin: increased risk of myopathy at high dose (80 mg)
Link  Drug Safety Update December 2014: Statins: risk of hyperglycaemia and diabetes
Link  Drug Safety Update December 2014: Systemic fusidic acid and interaction with statins
   
02.12  Expand sub section  Nicotinic acid group
02.12  Expand sub section  Omega-3 fatty acid compounds
02.12  Expand sub section  PCSK9 inhibitors
02.12  Expand sub section  Other lipid modifying agents
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Little or no specific monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Brief prescribing document or information sheet may be required.  

Amber 1

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Minimal monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Full prior agreement about patient’s on-going care must be reached under the shared care agreement.  

Amber 2

Initiated by specialist and transferred to primary care following a successful initiation period. Significant monitoring required on an on-going basis. Full prior agreement about patient’s on-going care must be reached under the shared care agreement. Suitable for enhanced service.  

Black

NOT recommended for use by the NHS in Lancashire. Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.  

Blue

Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information  

Green

Appropriate for initiation and ongoing prescribing in both primary and secondary care. Generally, little or no routine drug monitoring is required.  

Purple

Low Priority for Prescribing - see Low Priority for Prescribing Policy  

Red

Medicine is supplied by the hospital for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.  

Red Specialist Centre

Prescribing restricted to Specialist Centres only  

netFormulary